Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
CRNX Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call shows strong revenue growth and improved net loss, but also highlights increased R&D expenses and a recent equity offering, which can dilute share value. The lack of strategic updates or risk discussions, coupled with unclear management responses in the Q&A, suggests uncertainty. Given the market cap, these mixed signals balance out to a neutral sentiment, indicating a likely stock price fluctuation within -2% to 2% over the next two weeks.
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlights a strong revenue growth forecast (15%-20%) and improved operating margins, alongside successful product launches and market expansion in endocrinology. Despite a net loss, cost-cutting measures have improved financial health. The absence of explicit risks further supports a positive outlook. With a market cap of $3.4 billion, the positive guidance and strategic initiatives are likely to result in a moderate stock price increase of 2% to 8%.
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call highlights strong product development and market strategy, especially with the PALSONIFY launch and its appeal to both patients and prescribers. The Q&A section indicates effective execution and positive reception, despite minor uncertainties in payer approval timing. Financial guidance shows controlled cash usage, and the company is well-capitalized. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
CRNX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
